[go: up one dir, main page]

WO2002059558A3 - Means and methods for treatment evaluation - Google Patents

Means and methods for treatment evaluation Download PDF

Info

Publication number
WO2002059558A3
WO2002059558A3 PCT/NL2002/000051 NL0200051W WO02059558A3 WO 2002059558 A3 WO2002059558 A3 WO 2002059558A3 NL 0200051 W NL0200051 W NL 0200051W WO 02059558 A3 WO02059558 A3 WO 02059558A3
Authority
WO
WIPO (PCT)
Prior art keywords
sample
patient
treatment
angiogenesis
determining whether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2002/000051
Other languages
French (fr)
Other versions
WO2002059558A8 (en
WO2002059558A2 (en
Inventor
Der Kuyl Antoinette Cornel Van
Marion Cornelissen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMSTERDAM SUPPORT DIAGNOSTICS BV
AMSTERDAM SUPPORT DIAGNOSTICS
Original Assignee
AMSTERDAM SUPPORT DIAGNOSTICS BV
AMSTERDAM SUPPORT DIAGNOSTICS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01203703A external-priority patent/EP1298221A1/en
Application filed by AMSTERDAM SUPPORT DIAGNOSTICS BV, AMSTERDAM SUPPORT DIAGNOSTICS filed Critical AMSTERDAM SUPPORT DIAGNOSTICS BV
Priority to NZ526924A priority Critical patent/NZ526924A/en
Priority to JP2002559626A priority patent/JP2004523232A/en
Publication of WO2002059558A2 publication Critical patent/WO2002059558A2/en
Publication of WO2002059558A3 publication Critical patent/WO2002059558A3/en
Anticipated expiration legal-status Critical
Publication of WO2002059558A8 publication Critical patent/WO2002059558A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a method for determining whether a treatment is effective in changing the status of a certain set of target cells, such as a tumor, in a patient. This method implies obtaining a sample from a patient after initiation of a treatment, and determining whether said sample comprises an expression product of at least one marker gene. Preferably, said sample is a blood sample. In one aspect, said expression product is expressed by a peripheral blood mononuclear cell. Said marker gene may be a gene involved in the generation, maintenance and/or breakdown of blood vessels (angiogenesis). A method of the invention is very suitable to determine within a few days if a certain treatment against Kaposi's Sarcoma is successful. Moreover, this method is suitable for determining the presence of angiogenesis and/or tumor cells in a patient.
PCT/NL2002/000051 2001-01-23 2002-01-23 Means and methods for treatment evaluation Ceased WO2002059558A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ526924A NZ526924A (en) 2001-01-23 2002-01-23 Means and methods for treatment evaluation
JP2002559626A JP2004523232A (en) 2001-01-23 2002-01-23 Means and methods of treatment evaluation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP01200228.3 2001-01-23
EP01200228 2001-01-23
US32572201P 2001-09-28 2001-09-28
EP01203703A EP1298221A1 (en) 2001-09-28 2001-09-28 Means and methods for treatment evaluation
US60/325,722 2001-09-28
EP01203703.2 2001-09-28

Publications (3)

Publication Number Publication Date
WO2002059558A2 WO2002059558A2 (en) 2002-08-01
WO2002059558A3 true WO2002059558A3 (en) 2003-01-09
WO2002059558A8 WO2002059558A8 (en) 2003-11-06

Family

ID=27224257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2002/000051 Ceased WO2002059558A2 (en) 2001-01-23 2002-01-23 Means and methods for treatment evaluation

Country Status (4)

Country Link
JP (1) JP2004523232A (en)
CA (1) CA2369183A1 (en)
NZ (2) NZ537458A (en)
WO (1) WO2002059558A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2027470B1 (en) * 2006-06-02 2012-11-21 Pfizer Products Inc. Circulating tumor cell assay

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470824A (en) * 1991-05-31 1995-11-28 The Regents Of The University Of California Method to treat Kaposi's sarcoma
US5827658A (en) * 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
WO1998053319A2 (en) * 1997-05-21 1998-11-26 The Johns Hopkins University Gene expression profiles in normal and cancer cells
US5955429A (en) * 1997-01-29 1999-09-21 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
WO2000063438A2 (en) * 1999-04-20 2000-10-26 Curagen Corporation Method of classifying a thyroid carcinoma using differential gene expression
WO2001012172A1 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470824A (en) * 1991-05-31 1995-11-28 The Regents Of The University Of California Method to treat Kaposi's sarcoma
US5827658A (en) * 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5955429A (en) * 1997-01-29 1999-09-21 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
WO1998053319A2 (en) * 1997-05-21 1998-11-26 The Johns Hopkins University Gene expression profiles in normal and cancer cells
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
WO2000063438A2 (en) * 1999-04-20 2000-10-26 Curagen Corporation Method of classifying a thyroid carcinoma using differential gene expression
WO2001012172A1 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 21 November 1994 (1994-11-21), LINBERG AND HUNTER: "Human protein tyrosine kinase mRNA, complete cds", XP002207241, Database accession no. M59371 *
LINBERG R A ET AL: "CDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 10, no. 12, 1 December 1990 (1990-12-01), pages 6316 - 6324, XP000615509 *
OGAWA KAZUSHIGE ET AL: "The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.", ONCOGENE, vol. 19, no. 52, 2000, pages 6043 - 6052, XP001024674, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
NZ526924A (en) 2005-09-30
CA2369183A1 (en) 2002-07-23
NZ537458A (en) 2007-02-23
WO2002059558A8 (en) 2003-11-06
JP2004523232A (en) 2004-08-05
WO2002059558A2 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
WO2004041348A3 (en) Apparatus and method for pattern delivery of radiation and biological characteristic analysis
Takamiya et al. Immunohistochemical study of basic fibroblast growth factor and vascular endothelial growth factor expression for age determination of cutaneous wounds
WO2003027248A8 (en) Antibody inhibitors of gdf-8 and uses thereof
WO2001045730A3 (en) Tweak receptor
WO1999047669A3 (en) Human nucleic acid sequences from tissue of breast tumors
MXPA02006145A (en) Method for isolation of rna from formalinfixed paraffinembedded tissue specimens.
WO2003017745A8 (en) Architecture tool and methods of use
CA2362251A1 (en) Methods for preserving dna integrity
WO2003048333A3 (en) Endorepellin compositions and methods for inhibiting angiogenesis
WO2003000129A3 (en) Microdialysis probes and methods of use
BR9906926A (en) Compositions and methods for treating cells having double minute dna
WO2006025028A3 (en) Novel classification method of blood cells and tailor-made therapy and prevention based thereupon
WO2000018961A3 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
WO2002090925A3 (en) Polypeptides and nucleic acids associated with cancer
EP1225233A3 (en) Means and methods for treatment evaluation
WO2002059558A3 (en) Means and methods for treatment evaluation
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2001048180A3 (en) Method and apparatus for targeting localised electroporation
WO2005042723A3 (en) Novel multipotent stem cells and use thereof
FR2827176B1 (en) METHOD FOR RELIABILITY OF THE TRACEABILITY OF BLOOD SAMPLES DURING EXTRACTION OPERATIONS, IN PARTICULAR PLASMA AND RED CELLS
WO2002020003A3 (en) Use of carp inhibitors for the treatment of heart diseases
WO2002040059A3 (en) Methods and compositions for inducing cell-mediated immune responses
WO2001081361A8 (en) Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2003081239A3 (en) Treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002228477

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 526924

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002559626

Country of ref document: JP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 31/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

Free format text: IN PCT GAZETTE 31/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 526924

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526924

Country of ref document: NZ